DNA/RNA-based electrochemical nanobiosensors for early detection of cancers
In conclusion, nucleic acids-based electrochemical biosensors hold significant potential to enhance cancer detection and treatment through early and accurate diagnosis.PMID:38450458 | DOI:10.1080/10408363.2024.2321202 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 7, 2024 Category: Cancer & Oncology Authors: Babak Mikaeeli Kangarshahi Seyed Morteza Naghib Navid Rabiee Source Type: research
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
CONCLUSION: Rucaparib demonstrated acceptable toxicity and efficacy signal as an ADT-sparing approach in patients with biochemically recurrent nonmetastatic prostate cancer. It is currently challenging to understand the optimal value of systemic therapy in this disease setting due to the rapidly changing standard of care. Additionally, there are relatively few patients with BRCAness who present with nonmetastatic hormone-sensitive prostate cancer (ClinicalTrials.gov Identifier: NCT03533946).PMID:38452035 | DOI:10.1093/oncolo/oyae030 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 7, 2024 Category: Cancer & Oncology Authors: Kamal Kant Sahu Haoran Li Vinay Mathew Thomas Mallory Benson Ken Boucher Sumati Gupta Manish Kohli Umang Swami Neeraj Agarwal Benjamin L Maughan Source Type: research
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: Despite a statistically significant rPFS improvement in the all-comer cohort, FDA did not consider the magnitude of rPFS clinically meaningful in the context of the broad indication, combination treatment, and safety profile. Approval was therefore limited to patients with HRRm mCRPC, for whom there was a statistically significant and clinically meaningful improvement in rPFS and favorable OS results. This represents the first approval for the first-line treatment of patients with HRRm mCRPC.PMID:38452327 | DOI:10.1200/JCO.23.02182 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 7, 2024 Category: Cancer & Oncology Authors: Brian L Heiss Elaine Chang Xin Gao Tien Truong Michael H Brave Erik Bloomquist Ankit Shah Salaheldin Hamed Jeffrey Kraft Haw-Jyh Chiu Tiffany K Ricks Amy Tilley William F Pierce Liuya Tang Abdelrahmman Abukhdeir Shyam Kalavar Reena Philip Shenghui Tang Ri Source Type: research
Focal high-intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study
CONCLUSIONS: This interim analysis of a multinational study on HIFU therapy for the management of low-to-intermediate-risk PCa reveals good functional outcomes, minimal adverse events and low incidence of TF over the short-term. Data on long-term outcomes, specifically as it relates to oncological outcomes, are awaited eagerly.PMID:38445798 | DOI:10.1111/eci.14192 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 6, 2024 Category: Cancer & Oncology Authors: Sam Ladjevardi Anna Ebner Aleksandar Femic Nicolai A Huebner Shahrokh F Shariat Simon Kraler Rahel A Kubik-Huch Rafaele C Ahlman Michael H äggman Lukas J Hefermehl Source Type: research
Projection of the number of new cases of prostate cancer in the world
Jpn J Clin Oncol. 2024 Mar 5:hyae030. doi: 10.1093/jjco/hyae030. Online ahead of print.NO ABSTRACTPMID:38446798 | DOI:10.1093/jjco/hyae030 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 6, 2024 Category: Cancer & Oncology Authors: Hadrien Charvat Sumiyo Okawa Source Type: research
Fat intake modifies association between cigarette smoking and lung cancer in a prospective cohort study: A potential explanation for the lung cancer paradox
CONCLUSIONS: The present study showed that lung cancer risk associated with both the status and accumulated amount of cigarette smoking was remarkably stronger in individuals with high intakes of fat, particularly saturated fat. However, this interaction was not statistically significant and thus warrants further investigations in other studies.PMID:38447490 | DOI:10.1016/j.clnu.2024.02.021 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 6, 2024 Category: Cancer & Oncology Authors: Michael Reger Margaret Hoyt Haocheng Nan Hao Fan Jianjun Zhang Source Type: research
MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study
CONCLUSION: This study establishes the feasibility of online-MRIgRT for localised prostate on a 1.5 T MR-Linac with low rates of toxicity, similar to that published in the literature. However, the clinical benefits of MRIgRT over conventional radiotherapy in the setting of moderate hypofractionation is not evident. Further research will focus on the delivery of ultrahypofractionated regimens, where the potential advantages of MRIgRT for prostate cancer may become more discernible.PMID:38440792 | PMC:PMC10909700 | DOI:10.1016/j.ctro.2024.100742 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 5, 2024 Category: Cancer & Oncology Authors: Kobika Sritharan Lois Daamen Angela Pathmanathan Tine Schytte Floris Pos Ananya Choudhury Jochem R N van der Voort van Zyp Linda G W Kerkmeijer William Hall Emma Hall Helena M Verkooijen Trina Herbert Shaista Hafeez Adam Mitchell Alison C Tree Source Type: research
Response to "Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients - A closer inspection will improve your vision"
Clin Transl Radiat Oncol. 2024 Feb 21;46:100755. doi: 10.1016/j.ctro.2024.100755. eCollection 2024 May.NO ABSTRACTPMID:38440793 | PMC:PMC10909692 | DOI:10.1016/j.ctro.2024.100755 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 5, 2024 Category: Cancer & Oncology Authors: D Baron D Pasquier T Pace-Loscos B Vandendorpe R Schiappa C Ortholan J M Hannoun-Levi Source Type: research
MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study
CONCLUSION: This study establishes the feasibility of online-MRIgRT for localised prostate on a 1.5 T MR-Linac with low rates of toxicity, similar to that published in the literature. However, the clinical benefits of MRIgRT over conventional radiotherapy in the setting of moderate hypofractionation is not evident. Further research will focus on the delivery of ultrahypofractionated regimens, where the potential advantages of MRIgRT for prostate cancer may become more discernible.PMID:38440792 | PMC:PMC10909700 | DOI:10.1016/j.ctro.2024.100742 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 5, 2024 Category: Cancer & Oncology Authors: Kobika Sritharan Lois Daamen Angela Pathmanathan Tine Schytte Floris Pos Ananya Choudhury Jochem R N van der Voort van Zyp Linda G W Kerkmeijer William Hall Emma Hall Helena M Verkooijen Trina Herbert Shaista Hafeez Adam Mitchell Alison C Tree Source Type: research
Response to "Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients - A closer inspection will improve your vision"
Clin Transl Radiat Oncol. 2024 Feb 21;46:100755. doi: 10.1016/j.ctro.2024.100755. eCollection 2024 May.NO ABSTRACTPMID:38440793 | PMC:PMC10909692 | DOI:10.1016/j.ctro.2024.100755 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 5, 2024 Category: Cancer & Oncology Authors: D Baron D Pasquier T Pace-Loscos B Vandendorpe R Schiappa C Ortholan J M Hannoun-Levi Source Type: research
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
CONCLUSIONS: The RS-DAT met BE criteria (range 80%-125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC 0-24h,ss. The LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC 0-72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC 0-24h,ss; and the percentage of simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.GOV IDENTIFIER: NCT04577833.PMID:38436924 | DOI:10.1007/s40262-023-01340-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Alex Yu Anasuya Hazra James Juhui Jiao Peter Hellemans Anna Mitselos Hui Tian Juan Jose Perez Ruixo Nahor Haddish-Berhane Daniele Ouellet Alberto Russu Source Type: research
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
CONCLUSIONS: The RS-DAT met BE criteria (range 80%-125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC 0-24h,ss. The LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC 0-72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC 0-24h,ss; and the percentage of simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.GOV IDENTIFIER: NCT04577833.PMID:38436924 | DOI:10.1007/s40262-023-01340-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Alex Yu Anasuya Hazra James Juhui Jiao Peter Hellemans Anna Mitselos Hui Tian Juan Jose Perez Ruixo Nahor Haddish-Berhane Daniele Ouellet Alberto Russu Source Type: research
Ejaculation Frequency and Prostate Cancer Risk: A Narrative Review of Current Evidence
Clin Genitourin Cancer. 2024 Feb 1;22(3):102043. doi: 10.1016/j.clgc.2024.01.015. Online ahead of print.ABSTRACTProstate cancer, constituting a substantial portion of global cancer incidence and mortality, prompts a critical examination of potential modifiers, notably ejaculation frequency. This narrative review explores the complex relationship between ejaculation frequency and prostate cancer risk, addressing the paucity of consensus and the intricate interplay of factors. The evidence drawn from eleven studies with diverse methodologies reveals a complex understanding of this association. While some studies suggest an i...
Source: Clinical Prostate Cancer - March 2, 2024 Category: Cancer & Oncology Authors: Emmanuel Kokori Gbolahan Olatunji David Timilehin Isarinade John Ehi Aboje Ikponmwosa Jude Ogieuhi Zainab Doyinsola Lawal Nathnael Abera Woldehana Muhammad Wajeeh Nazar Godfred Yawson Scott Nicholas Aderinto Source Type: research
Control4Life: A randomized controlled trial protocol examining the feasibility and efficacy of a combined pelvic health rehabilitation and exercise fitness program for individuals undergoing prostatectomy
CONCLUSION: This study will inform the feasibility of offering comprehensive exercise programming that has the potential to positively impact urinary continence, erectile function and cardiometabolic health of individuals undergoing prostatectomy for prostate cancer.CLINICALTRIALS REGISTRATION NUMBER: NCT06072911.PMID:38431130 | DOI:10.1016/j.cct.2024.107482 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 2, 2024 Category: Cancer & Oncology Authors: St éphanie Bernard Howard Evans Nathan Hoy Kirsten Suderman Bruce Cameron John Sexsmith Adam Kinnaird Keith Rourke Lucas Dean Edith Pituskin Nawaid Usmani Puneeta Tandon Margaret L McNeely Source Type: research
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients - A closer inspection will improve your vision
Clin Transl Radiat Oncol. 2024 Feb 22;45:100754. doi: 10.1016/j.ctro.2024.100754. eCollection 2024 Mar.NO ABSTRACTPMID:38425470 | PMC:PMC10901823 | DOI:10.1016/j.ctro.2024.100754 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Cem Onal Aysenur Elmali Ozan Cem Guler Source Type: research
